Cost-utility analysis of second line acromegaly treatment in France
Annales d'Endocrinologie · 2025
DOI: 10.1016/j.ando.2025.101811 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Annales d'Endocrinologie, 2025. Verfasst von Gérald Raverot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, Centre de Référence des Maladies Rares de l'hypophyse HYPO, 69677 Bron…. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer SAS, Pfizer.
Abstract (Originalsprache)
OBJECTIVE: This updated French cost-utility analysis aimed to assess the efficacy of the second-line pharmacological treatment - pegvisomant, pasireotide or pegvisomant combined with first generation somatostatin analogues (FGSA) - considering first-line treatment (surgery, FGSA, cabergoline and combination), radiotherapy and the impact of treatment on tumor volume. METHODS: The original three-state Markov model was revised to include an additional health state, representing patients controlled without pharmacological treatment following successful radiotherapy. The model also accounted for the history of first-line treatments as additional costs upon patients' entry. A cohort of 1000 simulated patients was followed over a lifetime horizon from a collective perspective. Treatment efficacy is defined on normalization of insulin growth factor-1 and was determined through a network meta-analysis. Cost and utility data were sourced from French databases and literature. RESULTS: All the evaluated treatments were included in an efficiency frontier. The incremental cost-utility ratio (ICUR) of pegvisomant compared to pasireotide was 27,805€ per quality-adjusted life year (QALY) gained. The ICUR of pegvisomant combined with FGSA compared to pegvisomant was 253,854€/QALY. Sensitivity analyses showed the robustness of the results. The addition of radiotherapy has shown improved quality of life and lower costs for all second-line treatments. CONCLUSION: This model explores the cost-effectiveness of second-line pharmacological treatments of acromegaly accounting for the overall management recommended in France. Radiotherapy appears as a key therapeutic option allowing long-term remission of patients even after pharmacological treatment failure. This study is an additional tool for treatment choice including both a clinical and economic perspective. SIGNIFICANCE STATEMENT: The aim of this study is to assess the cost-utility of second-line treatments of acromegaly accounting for the overall management recommended in France, considering surgery, first-line treatments, radiotherapy and the impact of treatments on tumor volume, in addition to IGF-1 normalization. All evaluated treatments were included in an efficiency frontier. This addition has shown that radiotherapy and the impact on tumor volume are decisive in the management of second-line treatments for acromegaly. Indeed, radiotherapy enables patients to achieve complete remission, i.e. without the need for drug treatment. This is an important factor for patients, given that acromegaly treatments are chronic and usually lifelong. This study is an additional tool for treatment choice including both a clinical and economic perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, Centre de Référence des Maladies Rares de l'hypophyse HYPO, 69677 Bron, France.
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence d…
- CHU de Reims, Hôpital Robert-Debré, Service d'Endocrinologie-Diabète-Nutrition, Reims Cedex, France.
- Endocrinology Department, L'Institut du thorax, University Hospital of Nantes, Nantes Cedex, France.
- Endocrinology, Diabetology and Nutrition Department, Centre de Référence des Maladies Rares de l'hypophyse, University Hospital of Angers, Angers Cedex, France.
- Endocrinology, Diabetology and Nutrition Department, University Hospital of Bordeaux, Pessac, France.
Förderung
- Pfizer SAS
- Pfizer
Zitieren
APA
Raverot, G., Chanson, P., Delemer, B., Drui, D., Briet, C., Ferriere, A., Beillat, M., Aissani, W., Cabout, E., Ben Romdhane, H., & Brue, T. (2025). Cost-utility analysis of second line acromegaly treatment in France. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2025.101811
Vancouver
Raverot G, Chanson P, Delemer B, Drui D, Briet C, Ferriere A, et al. Cost-utility analysis of second line acromegaly treatment in France. Annales d'Endocrinologie. 2025. doi:10.1016/j.ando.2025.101811
BibTeX
@article{Raverot2025,
author = {Raverot, Gérald and Chanson, Philippe and Delemer, Brigitte and Drui, Delphine and Briet, Claire and Ferriere, Amandine and Beillat, Maud and Aissani, Wassila and Cabout, Elise and Ben Romdhane, Haifa and Brue, Thierry},
title = {Cost-utility analysis of second line acromegaly treatment in France},
journal = {Annales d'Endocrinologie},
year = {2025},
doi = {10.1016/j.ando.2025.101811}
}
EUVIMED